Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease - PubMed (original) (raw)
Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease
T Lehtimäki et al. Hum Genet. 1995 Jan.
Abstract
The apoE phenotype of 83 patients with probable Alzheimer's disease (AD) and of 164 non-demented controls was determined by isoelectric focusing and Western blotting. The proportion of the epsilon 4 allele was 0.548 in AD and 0.202 in controls (P < 0.0001). The effect was seen in both early-onset and late-onset AD patients. The risk of AD in epsilon 4 homozygotes was 18-fold greater than in individuals without the epsilon 4 allele. ApoE concentrations were measured in serum and cerebrospinal fluid (CSF) from a subgroup of patients with AD (n = 72) and controls (n = 84) by a sandwich enzyme-linked immunosorbent assay. Although serum apoE concentrations were lower in individuals with the epsilon 4 allele than in those without the epsilon 4 allele, CSF apoE concentrations did not vary in different phenotype groups. However, CSF apoE levels were lower in AD patients than in controls. We conclude that the inheritance of the epsilon 4 allele of apoE is a risk factor for AD in the Finnish population.
Similar articles
- APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis.
Fukumoto H, Ingelsson M, Gårevik N, Wahlund LO, Nukina N, Yaguchi Y, Shibata M, Hyman BT, Rebeck GW, Irizarry MC. Fukumoto H, et al. Exp Neurol. 2003 Sep;183(1):249-53. doi: 10.1016/s0014-4886(03)00088-8. Exp Neurol. 2003. PMID: 12957508 - Apolipoprotein E polymorphism and susceptibility to early- and late-onset sporadic Alzheimer's disease in Hokkaido, the northern part of Japan.
Nunomura A, Chiba S, Eto M, Saito M, Makino I, Miyagishi T. Nunomura A, et al. Neurosci Lett. 1996 Mar 8;206(1):17-20. doi: 10.1016/0304-3940(96)12415-0. Neurosci Lett. 1996. PMID: 8848271 Clinical Trial. - Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM. Martínez-Morillo E, et al. Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15. Acta Neuropathol. 2014. PMID: 24633805 - Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
Arai H, Higuchi S, Sasaki H. Arai H, et al. Gerontology. 1997;43 Suppl 1:2-10. doi: 10.1159/000213879. Gerontology. 1997. PMID: 9187933 Review. - Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription.
Laws SM, Hone E, Gandy S, Martins RN. Laws SM, et al. J Neurochem. 2003 Mar;84(6):1215-36. doi: 10.1046/j.1471-4159.2003.01615.x. J Neurochem. 2003. PMID: 12614323 Review.
Cited by
- Biomarkers of Alzheimer disease in plasma.
Irizarry MC. Irizarry MC. NeuroRx. 2004 Apr;1(2):226-34. doi: 10.1602/neurorx.1.2.226. NeuroRx. 2004. PMID: 15717023 Free PMC article. Review. - Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.
Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, Yu CE. Bekris LM, et al. J Alzheimers Dis. 2008 Apr;13(3):255-66. doi: 10.3233/jad-2008-13303. J Alzheimers Dis. 2008. PMID: 18430993 Free PMC article. - DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease.
Shao Y, Shaw M, Todd K, Khrestian M, D'Aleo G, Barnard PJ, Zahratka J, Pillai J, Yu CE, Keene CD, Leverenz JB, Bekris LM. Shao Y, et al. J Hum Genet. 2018 Apr;63(4):459-471. doi: 10.1038/s10038-017-0393-8. Epub 2018 Jan 25. J Hum Genet. 2018. PMID: 29371683 Free PMC article. - Upstream transcription factor 1 (USF1) polymorphisms associate with Alzheimer's disease-related neuropathological lesions: Tampere Autopsy Study.
Isotalo K, Kok EH, Luoto TM, Haikonen S, Haapasalo H, Lehtimäki T, Karhunen PJ. Isotalo K, et al. Brain Pathol. 2012 Nov;22(6):765-75. doi: 10.1111/j.1750-3639.2012.00586.x. Epub 2012 Apr 12. Brain Pathol. 2012. PMID: 22390463 Free PMC article. - CSF Apo-E levels associate with cognitive decline and MRI changes.
Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative. Toledo JB, et al. Acta Neuropathol. 2014 May;127(5):621-32. doi: 10.1007/s00401-013-1236-0. Epub 2014 Jan 3. Acta Neuropathol. 2014. PMID: 24385135 Free PMC article.
References
- Nature. 1991 Oct 31;353(6347):844-6 - PubMed
- Am J Hum Genet. 1988 Jan;42(1):104-12 - PubMed
- Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8098-102 - PubMed
- Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-81 - PubMed
- J Med Genet. 1994 Mar;31(3):197-200 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous